Human placenta-derived stem cells - recent findings based on the molecular science

Q4 Biochemistry, Genetics and Molecular Biology
Rafał Sibiak, Michał Jaworski, Zuzanna Dorna, W. Pieńkowski, K. Stefańska, Rut Bryl, J. Žáková, I. Crha, P. Ventruba, M. Ješeta, B. Kempisty
{"title":"Human placenta-derived stem cells - recent findings based on the molecular science","authors":"Rafał Sibiak, Michał Jaworski, Zuzanna Dorna, W. Pieńkowski, K. Stefańska, Rut Bryl, J. Žáková, I. Crha, P. Ventruba, M. Ješeta, B. Kempisty","doi":"10.2478/acb-2020-0021","DOIUrl":null,"url":null,"abstract":"Abstract The human placenta is a complex, multifunctional transient fetomaternal organ. The placenta is composed of the maternal decidua basalis and its fetal part, consisting of the mesenchymal and trophoblast cell lineages. Both the placenta and the amniotic membranes are abundant in readily available placenta-derived mesenchymal stem cells (PD-MSCs). The clinical application of the PD-MSCs opens new perspectives for regenerative medicine and the treatment of various degenerative disorders. Their properties depend on their paracrine activity – the secretion of the anti-inflammatory cytokines and specific exosomes. In contrast to the PD-MSCs, the trophoblast stem cells (TSCs) are much more elusive. They can only be isolated from the blastocyst-stage embryos or the first-trimester placental tissue, making that procedure quite demanding. Also, other cultures require specific, strictly controlled conditions. TSCs may be potentially used as an in vitro model of various placental pathologies, facilitating the elucidation of their mysterious pathogenesis and creating the environment for testing the new drug efficiency. Nonetheless, it is unlikely that they could be ever implemented as a part of novel cellular therapeutic strategies in humans. Running title: Current knowledge on the placental stem cells","PeriodicalId":18329,"journal":{"name":"Medical Journal of Cell Biology","volume":"8 1","pages":"164 - 169"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of Cell Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/acb-2020-0021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 1

Abstract

Abstract The human placenta is a complex, multifunctional transient fetomaternal organ. The placenta is composed of the maternal decidua basalis and its fetal part, consisting of the mesenchymal and trophoblast cell lineages. Both the placenta and the amniotic membranes are abundant in readily available placenta-derived mesenchymal stem cells (PD-MSCs). The clinical application of the PD-MSCs opens new perspectives for regenerative medicine and the treatment of various degenerative disorders. Their properties depend on their paracrine activity – the secretion of the anti-inflammatory cytokines and specific exosomes. In contrast to the PD-MSCs, the trophoblast stem cells (TSCs) are much more elusive. They can only be isolated from the blastocyst-stage embryos or the first-trimester placental tissue, making that procedure quite demanding. Also, other cultures require specific, strictly controlled conditions. TSCs may be potentially used as an in vitro model of various placental pathologies, facilitating the elucidation of their mysterious pathogenesis and creating the environment for testing the new drug efficiency. Nonetheless, it is unlikely that they could be ever implemented as a part of novel cellular therapeutic strategies in humans. Running title: Current knowledge on the placental stem cells
人类胎盘来源的干细胞——基于分子科学的最新发现
人胎盘是一个复杂的、多功能的瞬态胎母器官。胎盘由母体基底蜕膜及其胎儿部分组成,由间充质细胞系和滋养细胞系组成。胎盘和羊膜都富含胎盘源性间充质干细胞(PD-MSCs)。PD-MSCs的临床应用为再生医学和各种退行性疾病的治疗开辟了新的前景。它们的特性取决于它们的旁分泌活性——抗炎细胞因子和特定外泌体的分泌。与PD-MSCs相比,滋养细胞干细胞(TSCs)更加难以捉摸。它们只能从囊胚阶段的胚胎或妊娠早期的胎盘组织中分离出来,这使得这一过程非常困难。此外,其他文化需要特定的、严格控制的条件。tsc有可能作为多种胎盘病理的体外模型,有助于阐明其神秘的发病机制,并为测试新药的有效性创造环境。尽管如此,它们不太可能作为人类新细胞治疗策略的一部分实施。标题:关于胎盘干细胞的最新知识
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medical Journal of Cell Biology
Medical Journal of Cell Biology Biochemistry, Genetics and Molecular Biology-Cell Biology
自引率
0.00%
发文量
15
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信